CN1418635A - Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method - Google Patents
Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method Download PDFInfo
- Publication number
- CN1418635A CN1418635A CN 02156846 CN02156846A CN1418635A CN 1418635 A CN1418635 A CN 1418635A CN 02156846 CN02156846 CN 02156846 CN 02156846 A CN02156846 A CN 02156846A CN 1418635 A CN1418635 A CN 1418635A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- solution
- kinds
- adjuvant
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to an aspirin oral disintegrant tablet for curing common cold, its chemical name is acetylsalicylic acid, and its preparation method. Said invention provides its structural formula and its molecular formula, and its composition contains C9H8O4 and two kinds of six auxiliary material or one kind of eight auxiliary material. Said invention has three different preparation methods, and has the functions of analgesia, resisting inflammation, antipyretic, resisting rheumatism and inhibiting platelet aggregation.
Description
Technical field
The present invention relates to pharmaceutical, particularly relate to treatment flu Orally disintegrating tablet of aspirin, and preparation method thereof.
Background technology
Flu comprises common cold and influenza.Common cold: be the acute inflammation of upper respiratory tract such as nose, nasopharynx, throat, also often be referred to as acute upper respiratory tract infection, be called for short " going up sense ".Primary disease is common clinical, frequently-occurring disease, and sickness rate is higher.All can take place throughout the year, winter-spring season is seen at most.Can betide any age, the highest with children's's sickness rate.Often be sporadic, idol can cause popular.Influenza: be virogenetic a kind of acute respiratory infectious disease.Mainly by the spittle and direct contact infection, have hyperinfection, Chang Yi causes on a large scale even worldwide being very popular.Flu is normal to merge symptom such as have a headache and fever.The clinical dose that needs is very huge.
When people catch a cold etc. and to take medicine, must take medicine with boiled water.Take medicine when patient's water on the one hand, particularly old age and women and children patient are usually very inconvenient; Medicine can improve drug effect (bioavailability) widely and also play a role rapidly at the rapid disintegrate in oral cavity (common below 30 seconds) on the other hand.Therefore, medicine oral disintegrated preparation technology has become one of contemporary medical high-tech, and it will provide administering mode very easily for all kinds of patients.
Summary of the invention
The object of the present invention is to provide a kind of taking medicine conveniently, the obvious results oral cavity disintegration tablet, and preparation method thereof.
Purpose of the present invention can realize by following measure:
A kind of treatment cat fever Orally disintegrating tablet of aspirin is made up of principal agent and adjuvant, wherein
One, principal agent: aspirin:
A, English: Aspirin
B, chemical name: aspirin
C, structural formula:
D, molecular formula: C
9H
8O
4
Every contains principal agent 25-1000mg
Two, adjuvant: raw material is by weight percentage formed, and according to the preparation method difference, can adopt following three kinds of prescriptions:
1, forms by six kinds of adjuvants
A mannitol 5-80%
B sucrose 5-80%
C gelatin 0.1-10%
D hydroxyethyl-cellulose 0.1-7.5%
E lysine 1.0-30%
F spice 0.1-1.0%
2, form by six kinds of adjuvants
A mannitol 5-80%
B sucrose 5-80%
C gelatin 0.1-10%
D hydroxyethyl-cellulose 0.1-7.5%
E arginine 1.0-38%
F spice 0.1-1.0%
3, form by eight kinds of adjuvants
A glucose 10-50%
B compressibility sorbitol 10-50%
C mannitol 10-40%
D sucrose 10-40%
E sodium bicarbonate 5-20%
F citric acid 5-10%
G saccharin sodium 0.05%
H aspartame 0.05%.
The method for preparing Orally disintegrating tablet of aspirin: the principal agent aspirin is dissolved in earlier in the lysine solution, is suspended in then in the hydroxyethyl cellulose aqueous solution, form solution A, press the prescription in the adjuvant 1, gelatin, spice, mannitol and sucrose mixed dissolution, form solution B, add solution B mixing forming solution A, and add the dilution of an amount of water, and abundant mixing, join sharp freezing in the mould, put into the freeze dryer evacuation, ice sublimes up into material bone dry, press seal, packing;
Or the principal agent aspirin is dissolved in earlier in the arginine solution, be suspended in then in the hydroxyethyl cellulose aqueous solution, form solution X, press the prescription in the adjuvant 2, gelatin, spice, mannitol and sucrose mixed dissolution, form solution Y, add solution Y mixing forming solution X, and add the dilution of an amount of water, and abundant mixing, join sharp freezing in the mould, put into the freeze dryer evacuation, ice sublimes up into material bone dry, press seal, packing;
Or another preparation method of preparation Orally disintegrating tablet of aspirin, principal agent aspirin and eight kinds of adjuvants press prescription mix homogeneously in the adjuvant 3, add wetting agent or binding agent and make soft material, sieve oven dry, granulate, tabletting, packing behind the adding lubricant.
The present invention has following advantage compared to existing technology:
Oral instant-dissolving tablet is a kind of New Western medicine oral solid formulation that just occurs on the medical market abroad in recent years, the distinguishing feature of this dosage form is to use water delivery service, taking convenience, effect rapidly, running into saliva in the oral cavity just can dissolve rapidly, the patient of, infant bad to some functions of swallowing and child, water intaking inconvenience provides convenience, and has vast market prospect.
The specific embodiment
Enumerate three embodiment below, the present invention is further specified.
Embodiment 1
50 gram aspirin are dissolved in earlier in the 30 gram lysine solutions, be suspended in then in the 7.5 gram hydroxyethyl-celluloses, make solution A, then 2.5 gram gelatin, 0.5 gram spice, 25 gram sucrose and 34.5 gram mannitol mixed dissolutions, make solution B, solution A and solution B are mixed, add the suitable quantity of water dilution, and abundant mixing, put into the mould sharp freezing, evacuation in freeze dryer, ice sublimes up into material bone dry, press seal, packing.
The gross weight of six kinds of adjuvants is 100 grams, makes 1000,100 milligrams of every adjuvants, and 50 milligrams of aspirin of principal agent, promptly oral cavity disintegration tablet heavily is 150 milligrams.
Embodiment 2
100 the gram aspirin, earlier be dissolved in 20 the gram arginine solution in, be suspended in then in the 5 gram hydroxyethyl-celluloses, the raw material consumption in 1 is implemented in 10 gram gelatin, 1 gram spice, 15 gram mannitol and 49 gram sucrose replacements, method is 100 grams with the gross weight of 1, six kind of adjuvant of embodiment, makes 1000,100 milligrams of every adjuvants, 100 milligrams of aspirin, promptly every heavy 200 milligrams, every contains 100 milligrams of aspirin.
Embodiment 3
Glucose 30 grams, compressibility sorbitol 10 grams, mannitol 20 grams, sucrose 20 grams, sodium bicarbonate 10 grams, citric acid 9.9 grams, saccharin sodium 0.05 gram and aspartame 0.05 gram be totally eight kinds of adjuvant 100 grams, with aspirin 300 gram mix homogeneously, add wetting agent and make soft material, sieve, oven dry, granulate, tabletting behind the adding lubricant is made 1000, every heavy 400mg, wherein aspirin contains 300mg, adjuvant 100mg.
More than enumerate three embodiment, 50 milligrams, 100 milligrams, 300 milligrams of aspirin are totally three specifications, and when preparing this product, every sheet is heavy variable.Other contains the embodiment of aspirin 25-1000mg/ sheet, and method is the same.
The present invention is used for the treatment of (1) analgesia (2) antiinflammatory (3) analgesic (4) rheumatisms (5) anticoagulant.
Claims (2)
1, a kind of treatment flu Orally disintegrating tablet of aspirin is made up of principal agent and adjuvant, wherein
One, principal agent: aspirin:
A English: Aspirin
B chemical name: aspirin
The c structural formula:
D molecular formula: C
9H
8O
4
Every contains principal agent 25-1000mg
Two, adjuvant: raw material is by weight percentage formed, and according to the preparation method difference, can adopt following three kinds of prescriptions:
1, forms by six kinds of adjuvants
A mannitol 5-80%
B sucrose 5-80%
C gelatin 0.1-10%
D hydroxyethyl-cellulose 0.1-7.5%
E lysine 1.0-30%
F spice 0.1-1.0%
2, form by six kinds of adjuvants
A mannitol 5-80%
B sucrose 5-80%
C gelatin 0.1-10%
D hydroxyethyl-cellulose 0.1-7.5%
E arginine 1.0-38%
F spice 0.1-1.0%
3 are made up of eight kinds of adjuvants
A glucose 10-50%
B compressibility sorbitol 10-50%
C mannitol 10-40%
D sucrose 10-40%
E sodium bicarbonate 5-20%
F citric acid 5-10%
G saccharin sodium 0.05%
H aspartame 0.05%.
2, the method for preparation Orally disintegrating tablet of aspirin as claimed in claim 1, it is characterized in that being dissolved in the principal agent aspirin in the lysine solution earlier, be suspended in the hydroxyethyl cellulose aqueous solution then, form solution A, press the prescription in the adjuvant 1, gelatin, spice, mannitol and sucrose mixed dissolution, form solution B, add solution B mixing forming solution A, and add an amount of water dilution, and abundant mixing, join sharp freezing in the mould, put into the freeze dryer evacuation, ice sublimes up into material bone dry, press seal, packing;
Or the principal agent aspirin is dissolved in earlier in the arginine solution, be suspended in then in the hydroxyethyl cellulose aqueous solution, form solution X, press the prescription in the adjuvant 2, gelatin, spice, mannitol and sucrose mixed dissolution, form solution Y, add solution Y mixing forming solution X, and add the dilution of an amount of water, and abundant mixing, join sharp freezing in the mould, put into the freeze dryer evacuation, ice sublimes up into material bone dry, press seal, packing;
Or principal agent aspirin and eight kinds of adjuvants pressed prescription mix homogeneously in the adjuvant 3, and add wetting agent or binding agent and make soft material, sieve, oven dry, granulate adds tabletting behind the lubricant, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02156846 CN1418635A (en) | 2002-12-19 | 2002-12-19 | Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02156846 CN1418635A (en) | 2002-12-19 | 2002-12-19 | Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1418635A true CN1418635A (en) | 2003-05-21 |
Family
ID=4752827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02156846 Pending CN1418635A (en) | 2002-12-19 | 2002-12-19 | Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1418635A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008004386A1 (en) * | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Use of an acetylsalicylic acid salt for the treatment of viral infections |
| CN109789152A (en) * | 2016-06-28 | 2019-05-21 | 阿萨德股份有限公司 | Two-component composition |
| US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
| US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
-
2002
- 2002-12-19 CN CN 02156846 patent/CN1418635A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008004386A1 (en) * | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Use of an acetylsalicylic acid salt for the treatment of viral infections |
| CN109789152A (en) * | 2016-06-28 | 2019-05-21 | 阿萨德股份有限公司 | Two-component composition |
| US11369581B2 (en) | 2016-06-28 | 2022-06-28 | Asamedic As | Two component composition |
| US11918554B2 (en) | 2016-06-28 | 2024-03-05 | Asamedic As | Two-component composition |
| US11844806B2 (en) | 2017-12-22 | 2023-12-19 | Asamedic As | Compositions comprising acetylsalicylic acid and a phosphate salt |
| US11850253B2 (en) | 2017-12-22 | 2023-12-26 | Asamedic As | Two component compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008285434A (en) | Quickly disintegrating tablet in oral cavity | |
| CN1418631A (en) | Zopiclone oral disintegrant for treating insomnia, and its prepn. method | |
| CN1418635A (en) | Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method | |
| JP2007119453A (en) | Method for preventing lowering of bromhexine hydrochloride content | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
| CN1418624A (en) | Alizapride oral disintegrant for treating emesis | |
| CN101234094B (en) | Dipyridamole orally disintegrating tablet | |
| CN1771915A (en) | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn | |
| WO2005105109A1 (en) | Oral modified-release lozenges and their preparation method | |
| CN1419909A (en) | Oral cavity disintegrating tablet of diclofenac for treating inflammation and pain, and preparing method thereof | |
| CN1582955A (en) | Oral disintegrants of breviscapine for diseases of cardio-cerebral blood vessels and their preparation | |
| CN1418634A (en) | Prednisolone oral disintegrant for treating acute bacterial infection, and its prepn. method | |
| CN101627972B (en) | Entecavir orally disintegrating tablet and method for preparing same | |
| CN1418638A (en) | Ribavirin oral disintegrant for treating virus influenza, and its prepn. method | |
| CN1582917A (en) | Oral disintegrants of isosorbide mononitrate and their preparation | |
| CN1582920A (en) | Oral disintegrants of daidzein for treating cardio-vagal blood vessels diseases and their preparation | |
| CN1698640A (en) | Compound powder of Roxithromycin and ambroxol hydrochloride sustained adequate for children, its prescription and preparation method | |
| CN1418629A (en) | Tipepidine oral disintegrant for treating tussis and expectoration, and its prepn. method | |
| CN1418627A (en) | Nitrophendipine oral disintegrant for treating angina pectoris, and its prepn. method | |
| CN1872055A (en) | Compound preparation of amoxicillin and ambroxol hydrochloride suitable to use for children, prescription and preparation method | |
| CN1419910A (en) | Oral cavity disintegrating tablet of chlorphenamine for treating allergy, and preparing method thereof | |
| CN1582923A (en) | Oral disintegrants of indapamine for hypertension and their preparation | |
| CN100337628C (en) | Nimodipine oral disintegrant tablet for curing dementia and its preparation method | |
| CN1419908A (en) | Oral cavity disintegrating tablet of clenbuterol hydrochloride for treating asthma, and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |